Probation draws to a close for Bristol-Myers

Bristol-Myers Squibb is finally getting off probation with the end of its two-year deferred prosecution period today. "Bristol-Myers Squibb has made significant and transformational changes in its compliance practices as a result of the DPA [deferred prosecution agreement," said U.S. attorney Christopher J. Christie. The company agreed to stick to the letter of the law back in 2005 in order to escape prosecution for an illegal scheme known as channel stuffing.

- check out the statement from BMS
- read the MarketWatch report

ALSO: Bristol-Myers announced that its drug Orencia may be effective as a therapy against arthritis in children. Orencia is approved for adults. Report

Related Articles:
BMS board fires Dolan, general counsel. Report
Cornelius get big payday for BMS temp job. Report
FBI agents raid BMS office in deal probe. Report
Better times ahead for BMS? Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.